Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: Results from a phase I trial in cancer patients

Journal of Immunotherapy with Emphasis on Tumor Immunology

Volumn 19, Issue 4, 1996, Pages 296-308

  Curti, Brendan D ^a   Ochoa, Augusto C ^b   Urba, Walter J ^b   Gregory Alvord, W ^a   Kopp, William C ^b   Powers, Gerry ^b   Hawk, Connie ^a   Creekmore, Stephen P ^a   Gause, Barry L ^a   Janik, John E ^a   Holmlund, Jon T ^a   Kremers, Peter ^a   Fenton, Robert G ^a   Miller, Langdon ^c   Sznol, Mario ^a   Smith, John W ^a   Sharfman, William H ^a   Longo, Dan L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Anti CD3; IL 2; Lymphocytes; T cells

Indexed keywords

INDIUM 111; INTERLEUKIN 2;

ADOPTIVE TRANSFER; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CELL VIABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; KILLER CELL; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 9544237237     PISSN: 10675582     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Ochoa AC, Gromo G, Alter BJ, Sondel PM, Bach FH. Longterm growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-ILl, interferon-gamma and -beta. J Immunol 1987;138:2728-33.
2. Ting CC, Hargrove ME, Yun YS. Augmentation by anti-T3 antibody of the lymphokine-activated killer cell-mediated cytotoxicity. J Immunol 1988;141:741-8.
3. Hooks MA, Wade CS, Millikan WJ Jr. Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy 1991;11:26-37.
4. Urba WJ, Ewel C, Kopp W, et al. Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors: a phase IA/B study. Cancer Res 1992;52:2394-401.
5. Loeffler CM, Platt JL, Anderson PM, et al. Antitumor effects of interleukin 2 liposomes and anti-CD3-stimulated T-cells against murine MCA-38 hepatic metastasis. Cancer Res 1991;51:2127-32.
6. Curti BD, Longo DL, Ochoa AC, et al. Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and in terleukin-2. J Clin Oncol 1993;11:652-60.
7. Thompson JA, Lee DJ, Lindgren CG, et al. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells. Cancer Res 1989;49:235-40.
8. Clark JW, Smith JW II, Steis RG, et al. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen. Cancer Res 1990;50:7343-50.
9. Sznol M, Steis RG, Smith JW II, et al. Intensive therapy with cisplatin, interleukin-2 and interferon-alpha-2A in patients with metastatic melanoma: a phase II study. Online J Curr Clin Trials 1992;9.
10. Griffith KD, Read EJ, Carrasquillo JA, et al. In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. J Natl Cancer Inst 1989;81:1709-17.
11. Margolin KA, Rayner AA, Hawkins MJ, et al. lnterleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol 1989;7:486-98.
12. Goedegebuure PS, Zuber M, Leonard-Vidal DL, et al. Reactivation of murine tumour-infiltrating lymphocytes with solid-phase anti-CD3 antibody: in vitro cytokine production is associated with in vivo efficacy. Surg Oncol 1994;3:79-89.
13. Yun Y-S, Hargrove ME, Ting C-C. In vivo antitumor activity of anti-cd3-induced activated killer cells. Cancer Res 1989;49:4770-4.
14. Weil-Hillman G, Schell K, Segal DM, Hank JA, Sosman JA, Sondel PM. Activation of human T cells obtained pre- and post-interleukin-2 (IL-2) therapy by anti-cd3 monoclonal antibody plus IL-2: implications for combined in vivo treatment. J Immunother 1991;10:267-77.
15. Ochoa AC, Hasz DE, Rezonzew R, Anderson PM, Bach FH. Lymphokine-activated killer activity in long-term cultures with anti-CD3 interleukin 2: identification and isolation of effector subsets. Cancer Res 1989;49:963-8.
16. Sosman JA, Weiss GR, Margolin KA, et al. Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects. J Clin Oncol 1993;11:1496-505.
17. Hank JA, Albertini M, Wesley OH, et al. Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody along with interleukin-2 in patients with cancer. Clin Cancer Res 1995;1:481-91.
18. Sosman JA, Kefer C, Fisher Rl, Jacobs CD, Pumfery P, Ellis TM. A phase 1A/1B trial of anti-CD3 murine monoclonal antibody plus low-dose continuous-infusion interleukin-2 in advanced cancer patients. J Immunother 1995; 17:171-80.
19. Gold JE, Malamud SC, LaRose F, Seder R, Osband ME. Adoptive chemoimmunotherapy for the treatment of relapsed and refractory solid tumors using ex vivo activated memory T cells (autolymphocyte therapy) and cyclophosphamide. J Immunother 1993;13:213-21.
20. Graham S, Babayan RK, Lamm DL, et al. The use of ex vivo-activated memory T cells (autolymphocyte therapy) in the treatment of metastatic renal cell carcinoma: final results from a randomized, controlled, multisite study. Semin Urol 1993;11:27-34.
21. Wesselborg S, Janssen O, Kabelitz D. Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J Immunol 1993;150:4338-45.
22. Kabelitz D, Pohl T, Pechhold K. Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes. Immunol Today 1993;14:338-339.
23. Russell JH, Rush BJ, Abrams SI, Wang R. Sensitivity of T cells to anti-CD3-stimulated suicide is independent of functional phenotype. Eur J Immunol 1992;22:1655-8.
24. Wolf H, Muller Y, Salmen S, Wilmanns W, Jung G. Induction of anergy in resting human T lymphocytes by immobilized anti-CD3 antibodies. Eur J Immunol 1994;24:1410-7.
25. Dvorak AM, Ishizaka T. Human eosinophils in vitro: an ultrastructural morphology primer. Histol Histopathol 1994; 9:339-74.
26. Tai PC, Sun L, Spry CJ. Effects of IL-5, granulocyte/ macrophage colony-stimulating factor (GM-CSF) and IL-3 on the survival of human blood eosinophils in vitro. Clin Exp Immunol 1991;85:312-6.
27. Wierenga EA, Backx B, Snoek M, Koenderman L, Kapsenberg ML. Relative contributions of human types 1 and 2 T-helper cell-derived eosinophilotrophic cytokines to development of eosinophilia. Blood 1993;82:1471-9.
28. Rosenstein M, Ettinghausen SE, Rosenberg SA. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 1986; 137: 1735-42.
29. Ochoa JB, Curti B, Peitzman AB, et al. Increased circulating nitrogen oxides after human tumor immunotherapy: correlation with toxic hemodynamic changes. J Natl Cancer Instit 1992;84:864-7.
30. Bassenge E, Zanzinger J. Nitrates in different vascular beds, nitrate tolerance, and interactions with endothelial function. Am J Cardiol 1992;70:23-98.
31. Elkayam U. Tolerance to organic nitrates: evidence, mechanisms, clinical relevance, and strategies for prevention. Ann Intern Med 1991;114:667-77.
32. Rosenberg SA, Aebersold P, Cornetta K, et al. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990;323:570-8.